Ipsen, Rhythm Sign License Agreement For Programs In Metabolic Disorders
Under the terms of the agreement, Ipsen has granted Rhythm an exclusive worldwide license for research, development and commercialization of its melanocortin and ghrelin programs originating from Ipsen
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.